Fabienne has been managing since 2015 consulting missions in strategy and innovation within biotech, high-tech companies, business clusters and investment organizations in Life Sciences and Healthcare. She is enabling both traditional biotech/pharma and digital health business models.
She previously gained a strong expertise in knowledge management and competitive intelligence within Ipsen, a mid-sized pharmaceutical company, both as information director acting as business partner to R&D and commercial affiliates, and as scientific and competitive intelligence director supporting corporate strategy and business development.
Moreover, she is an investor as a business angel (Angels for Health), an expert for EIT Health business cluster, and a member of the investment committee of a French Technology Transfer Organization.
Dr Patrick Squiban (MD)
Patrick Squiban is CEO of Health & Biotech France, a biotherapy company involved in the development of Mesenchymal Stem Cells derived from umbilical cords.
After having obtained his M.D. degree from the University of Paris Medical School in 1981, Patrick spent more than 30 years in the pharmaceutical industry, in various positions in France and at International level.
He joined Boehringer Ingelheim as Product Manager in 1981. He was then Medical Director of Novo Nordisk France and Vice President Pharmacology and Medical Affairs of Zymogenetics in Seattle (1986-1997), then VP Regulatory and Medical Affairs of Transgene (1997– 2005).
He joined Innate Pharma as CMO, Executive Vice President Regulatory and Medical Affairs in 2005, and then Boehringer Ingelheim as the Oncology Clinical Reserch Unit Director in 2010.
In 2015 Patrick dedicated his activities to the french Health Investment Network, Angels Santé, and also as consultant for the Papearus consultancy network. He became CEO of Health and Biotech France in 2019.
Through his various positions, Patrick has developed a strong experience in clinical research & development, as well as in regulatory affairs in the Pharma and the Biotech fields
Mathieu Laouenan is General Manager Europe of Actavia a consulting firm specialized in helping companies to develop their activities in Asia. Before joining Actavia early 2020, Mathieu was 8 years General Manager APAC based in Singapore for a major multinational life Sciences company, Water Corporation. He is now based in Paris for Actavia.
Mathieu has worked more than 25 years in the lifesciences industry in very diverse international contexts. He is a commercial leader in the organization developing business opportunities, supporting customers for profitable management of projects & missions, from inception to completion.
He is also the life sciences, practice leader focused on transformation, business development, operations set-up, supply chain, and partnership management.
Mathieu’s expertise includes: General Management with company & Organisation transformation, M&A, research of distribution or commercial partners and creation of local entities, operational performance including restructuring. He is also experienced in International marketing including the development of regional strategies, product launch, brand performance optimization and market access.
Mathieu holds a dual Master of Physics/chemistry and business administration (Marseille St Jerome) and has always served Pharmaceutical, Life Sciences, Healthcare, Food & Chemical industries.
Emmanuel Montet is the General Manager of Actavia, a consulting firm specialized in helping companies to develop their activities in Asia. Before joining Actavia Emmanuel has worked 20 years in the Pharmaceutical sector where he was General Manager for Southeast Asia, Hong-Kong, Taiwan and India for Ipsen, Vice-President China and Asia Support Functions for Ipsen Asia, Finance Director – Ipsen Pharma SAS (Ipsen’s holding), Head of Industrial Control – GSK Biologicals, Internal Audit Manager of Rhone-Poulenc (now Sanofi-Aventis).
Emmanuel is Singapore based since 2015. Emmanuel’s expertise includes : company transformation, assistance to General Managers, research of distribution and commercial partners, support in operations set-up, commercialization across the value chain. His experience also includes the development of regional strategies, product launch, brand performance optimization and market access. Emmanuel holds a Master of finance and a post graduate degree in Business Administration, both from PSL University (Paris Dauphine).
Joseph Chou is an entrepreneur, investor, founder and CEO of Tokyo Future Style (TFS) Taiwan, the sole international partner of TFS Japan. TFS specializes in distributing new and innovative bioproducts and technology, including HCS Pharma’s Biomimesys®.
Joseph has over 45 years of leadership experience across public and private sectors, with a specific focus on telecommunication technologies. Early in his career, Chou served as the Director of the Joint Investment and Services Center in Taiwan’s Ministry of Economic Affairs, and as a Senior Advisor for the Industrial Technology Research Institute (ITRI). In these roles he identified firms in the U.S., including AT&T, Motorola and IBM, for strategic investment critical to the growth of Taiwan’s technology sector.
In 1985 Joseph left the Ministry and founded Taiwan Telecom Network Service company (TTN), the first licensed, private telecommunication company in the country to build and operate a national network infrastructure providing data communication services to banking industries and large enterprises—a precursor to Taiwan’s first internet service provider. Joseph believes that new semiconductor applications are among the most exciting recent developments in the pharmaceutical and biotech industries. He has enthusiastically introduced HCS Pharma to Taiwan, a global leader in semiconductor design and manufacturing. In 2020, all four major, government endorsed biotech research and development institutions in Taiwan—Academia Sinica, Industrial Technology Research Institute (ITRI), Development Center for Biotechnology (DCB) and National Health Research Institutes (NHRI) partnered with HCS Pharma to begin Biomimesys® trial implementations in their laboratories.